PMID- 37793040
OWN - NLM
STAT- MEDLINE
DCOM- 20240202
LR  - 20240206
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 161
IP  - 2
DP  - 2024 Feb 1
TI  - Comparison of DNA methylation and cytology tests in urine to detect upper tract 
      urothelial carcinoma: A paired-design diagnostic study.
PG  - 115-121
LID - 10.1093/ajcp/aqad116 [doi]
AB  - OBJECTIVES: To evaluate the diagnostic efficacy of a DNA methylation test, 
      compare that test with cytology alone, fluorescence in situ hybridization (FISH) 
      alone, and cytology plus FISH, and explore reasons that may influence the 
      accuracy of liquid biopsy. METHODS: We included 37 patients and 12 negative 
      control individuals between April 2019 and May 2022. All patients had undergone 
      radical nephroureterectomy, nephrectomy, diagnostic ureteroscopy, or tissue 
      biopsy. Urine samples were collected for DNA methylation testing, cytology, and 
      FISH. Test performance was calculated, and receiver operating characteristic 
      curves were drawn for comparison. RESULTS: Median patient age was 66 years, and 
      kappa = 0.576 (P < .001) for the DNA methylation test and tissue pathology. The 
      sensitivity, specificity, positive predictive value (PPV), and negative 
      predictive value (NPV) of the DNA methylation test were 76%, 100%, 100%, and 74%, 
      respectively, compared with 31%, 100%, 100%, and 50%, respectively, for cytology. 
      The sensitivity, specificity, PPV, and NPV of cytology plus FISH were 66%, 100%, 
      100%, and 67%, respectively. The area under the curve (AUC) of the DNA 
      methylation test was 0.879 (P < .001), and the AUC of cytology plus FISH was 
      0.828 (P < .001). CONCLUSIONS: The test performance of DNA methylation was 
      satisfactory. The DNA methylation test for the detection of upper tract 
      urothelial carcinoma demonstrated better sensitivity than did cytology alone or 
      cytology with FISH, but the accuracy of the combined tests was still acceptable. 
      Further prospective studies with larger samples are needed to confirm the 
      clinical value of this promising method.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of American 
      Society for Clinical Pathology. All rights reserved. For permissions, please 
      e-mail: journals.permissions@oup.com.
FAU - Wei, Wei
AU  - Wei W
AUID- ORCID: 0000-0002-3427-2122
AD  - Department of Urology, Henan Provincial People's Hospital, Zhengzhou University 
      People's Hospital, Zhengzhou, China.
FAU - Wu, Danting
AU  - Wu D
AD  - Department of Pathology, Henan Provincial People's Hospital, Zhengzhou University 
      People's Hospital, Zhengzhou, China.
FAU - Zhang, Zhishu
AU  - Zhang Z
AD  - Department of Urology, Henan Provincial People's Hospital, Zhengzhou University 
      People's Hospital, Zhengzhou, China.
FAU - Liu, Junfeng
AU  - Liu J
AD  - Department of Urology, Henan Provincial People's Hospital, Zhengzhou University 
      People's Hospital, Zhengzhou, China.
FAU - Deng, Jun
AU  - Deng J
AD  - Department of Urology, Henan Provincial People's Hospital, Zhengzhou University 
      People's Hospital, Zhengzhou, China.
FAU - Zhang, Xiaoli
AU  - Zhang X
AD  - Department of Urology, Henan Provincial People's Hospital, Zhengzhou University 
      People's Hospital, Zhengzhou, China.
FAU - Ding, Degang
AU  - Ding D
AD  - Department of Urology, Henan Provincial People's Hospital, Zhengzhou University 
      People's Hospital, Zhengzhou, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
SB  - IM
MH  - Humans
MH  - Aged
MH  - *Carcinoma, Transitional Cell/pathology
MH  - *Urinary Bladder Neoplasms/pathology
MH  - DNA Methylation
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Prospective Studies
MH  - Sensitivity and Specificity
OTO - NOTNLM
OT  - DNA methylation
OT  - cytology
OT  - fluorescence in situ hybridization
OT  - upper tract urothelial carcinoma
OT  - urine sample
EDAT- 2023/10/04 18:42
MHDA- 2024/02/02 06:43
CRDT- 2023/10/04 15:13
PHST- 2023/06/09 00:00 [received]
PHST- 2023/08/15 00:00 [accepted]
PHST- 2024/02/02 06:43 [medline]
PHST- 2023/10/04 18:42 [pubmed]
PHST- 2023/10/04 15:13 [entrez]
AID - 7289073 [pii]
AID - 10.1093/ajcp/aqad116 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2024 Feb 1;161(2):115-121. doi: 10.1093/ajcp/aqad116.